Discovery Laboratories (DSCO +4.9%) moves up today after releasing data from a new...

|By:, SA News Editor

Discovery Laboratories (DSCO +4.9%) moves up today after releasing data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with Surfaxin may also result in an average potential hospital cost savings of $389,247 per 100 treated infants by reducing the frequency of bronchopulmonary dysplasia.